RESUMO
BACKGROUND AND PURPOSE: Hydrogen sulphide (H2S) is a gaseous mediator strongly involved in cardiovascular homeostasis, where it provokes vasodilatation. Having previously shown that H2 S contributes to testosterone-induced vasorelaxation, here we aim to uncover the mechanisms underlying this effect. EXPERIMENTAL APPROACH: H2 S biosynthesis was evaluated in rat isolated aortic rings following androgen receptor (NR3C4) stimulation. Co-immunoprecipitation and surface plasmon resonance analysis were performed to investigate mechanisms involved in NR3C4 activation. KEY RESULTS: Pretreatment with NR3C4 antagonist nilutamide prevented testosterone-induced increase in H2S and reduced its vasodilator effect. Androgen agonist mesterolone also increased H2S and induced vasodilatation; effects attenuated by the selective cystathionine-γ lyase (CSE) inhibitor propargylglycine. The NR3C4-multicomplex-derived heat shock protein 90 (hsp90) was also involved in this effect; its specific inhibitor geldanamycin strongly reduced testosterone-induced H2S production. Neither progesterone nor 17-ß-oestradiol induced H2S release. Furthermore, we demonstrated that CSE, the main vascular H2S-synthesizing enzyme, is physically associated with the NR3C4/hsp90 complex and the generation of such a ternary system represents a key event leading to CSE activation. Finally, H2S levels in human blood collected from male healthy volunteers were higher than those in female samples. CONCLUSIONS AND IMPLICATIONS: We demonstrated that selective activation of the NR3C4 is essential for H2S biosynthesis within vascular tissue, and this event is based on the formation of a ternary complex between cystathionine-γ lyase, NR3C4and hsp90. This novel molecular mechanism operating in the vasculature, corroborated by higher H2S levels in males, suggests that the L-cysteine/CSE/H2S pathway may be preferentially activated in males leading to gender-specific H2S biosynthesis.
Assuntos
Sulfeto de Hidrogênio/metabolismo , Receptores Androgênicos/metabolismo , Testosterona/farmacologia , Vasodilatação/efeitos dos fármacos , Adulto , Alcinos/farmacologia , Antagonistas de Androgênios/farmacologia , Animais , Aorta Torácica/efeitos dos fármacos , Aorta Torácica/metabolismo , Feminino , Glicina/análogos & derivados , Glicina/farmacologia , Humanos , Imidazolidinas/farmacologia , Masculino , Pessoa de Meia-Idade , Ratos , Ratos Wistar , Receptores Androgênicos/efeitos dos fármacos , Fatores Sexuais , Vasodilatadores/farmacologiaRESUMO
BACKGROUND AND PURPOSE: Sphingosine-1-phosphate (S1P) has been shown to be involved in the asthmatic disease as well in preclinical mouse experimental models of this disease. The aim of this study was to understand the mechanism(s) underlying S1P effects on the lung. EXPERIMENTAL APPROACH: BALB/c, mast cell-deficient and Nude mice were injected with S1P (s.c.) on days 0 and 7. Functional, molecular and cellular studies were performed. KEY RESULTS: S1P administration to BALB/c mice increased airway smooth muscle reactivity, mucus production, PGD2 , IgE, IL-4 and IL-13 release. These features were associated to a higher recruitment of mast cells to the lung. Mast cell-deficient Kit (W) (-sh/) (W) (-sh) mice injected with S1P did not display airway smooth muscle hyper-reactivity. However, lung inflammation and IgE production were still present. Treatment in vivo with the anti-CD23 antibody B3B4, which blocks IgE production, inhibited both S1P-induced airway smooth muscle reactivity in vitro and lung inflammation. S1P administration to Nude mice did not elicit airway smooth muscle hyper-reactivity and lung inflammation. Naïve (untreated) mice subjected to the adoptive transfer of CD4+ T-cells harvested from S1P-treated mice presented all the features elicited by S1P in the lung. CONCLUSIONS AND IMPLICATIONS: S1P triggers a cascade of events that sequentially involves T-cells, IgE and mast cells reproducing several asthma-like features. This model may represent a useful tool for defining the role of S1P in the mechanism of action of currently-used drugs as well as in the development of new therapeutic approaches for asthma-like diseases.
Assuntos
Hiper-Reatividade Brônquica/imunologia , Lisofosfolipídeos/imunologia , Pneumonia/imunologia , Esfingosina/análogos & derivados , Animais , Hiper-Reatividade Brônquica/sangue , Linfócitos T CD4-Positivos/imunologia , Imunoglobulina E/sangue , Interleucina-13/imunologia , Interleucina-4/imunologia , Mastócitos/imunologia , Camundongos Endogâmicos BALB C , Camundongos Knockout , Camundongos Nus , Pneumonia/sangue , Prostaglandina D2/sangue , Esfingosina/imunologiaRESUMO
BACKGROUND AND PURPOSE: Proteinase-activated receptors (PARs) and toll-like receptors (TLRs) are involved in innate immune responses. The aim of this study was to evaluate the possible cross-talk between PAR(2) and TLR4 in vessels in physiological condition and how it varies following stimulation of TLR4 by using in vivo and ex vivo models. EXPERIMENTAL APPROACH: Thoracic aortas were harvested from both naïve and endotoxaemic rats for in vitro studies. Arterial blood pressure was monitored in anaesthetized rats in vivo. LPS was used as a TLR4 agonist while PAR(2) activating peptide (AP) was used as a PAR(2) agonist. Aortas harvested from TLR4(-/-) mice were also used to characterize the PAR(2) response. KEY RESULTS: PAR(2) , but not TLR4, expression was enhanced in aortas of endotoxaemic rats. PAR(2) AP-induced vasorelaxation was increased in aortic rings of LPS-treated rats. TLR4 inhibitors, curcumine and resveratrol, reduced PAR(2) AP-induced vasorelaxation and PAR(2) AP-induced hypotension in both naïve and endotoxaemic rats. Finally, in aortic rings from TLR4(-/-) mice, the expression of PAR(2) was reduced and the PAR(2) AP-induced vasodilatation impaired compared with those from wild-type mice and both resveratrol and curcumine were ineffective. CONCLUSIONS AND IMPLICATIONS: Cross-talk between PAR(2) and TLR4 contributes to vascular homeostasis.
Assuntos
Aorta Torácica/fisiologia , Receptor PAR-2/fisiologia , Receptor 4 Toll-Like/fisiologia , Animais , Hipotensão/induzido quimicamente , Hipotensão/fisiopatologia , Técnicas In Vitro , Lipopolissacarídeos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Oligopeptídeos , Ratos , Ratos Wistar , Vasodilatação/fisiologiaRESUMO
Lipopolysaccharide (LPS) or endotoxin, the major constituent of the outer membrane of Gram negative bacteria, has been implicated as the bacterial product responsible for the clinical syndrome of sepsis. LPS binding to the host receptor Toll-like receptor 4 (TLR4) triggers an inflammatory reaction characterised by the release of large number of inflammatory mediators that allow the host to respond to the invading pathogen. When this production becomes un-controlled and excessive, it leads to the development of septic shock. Despite decades of efforts in supporting therapies, sepsis remains the leading cause of death amongst critically ill patients. Unfortunately, the major factor contributing to the high morbidity and mortality of sepsis is the lack of the effective targeted treatment. Indeed, over 30 drugs for the treatment of sepsis have been developed: many of these target specific inflammatory mediators and have thus been, in general, unsuccessful since sepsis relies on the cross talk of several cytokines and the block of a single factor has been proven to be ineffective. More successful strategies include those modulating the early phase of LPS signalling such as the ones that prevent the binding of LPS to host cells and the subsequent cascade of detrimental events. In this light, effective LPS antagonists would represent invaluable tools to efficaciously manage sepsis. This review discusses the evolution of naturally occurring and synthetic LPS antagonists with emphasis on the development of several natural new molecules.
Assuntos
Lipopolissacarídeos/antagonistas & inibidores , Sepse/tratamento farmacológico , Animais , Humanos , Lipídeo A/análogos & derivados , Lipídeo A/antagonistas & inibidores , Lipídeo A/farmacologia , Lipopolissacarídeos/química , Lipopolissacarídeos/farmacologia , Estrutura Molecular , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologiaRESUMO
Although thiazolidinediones were designed as specific peroxisome proliferator-activated receptor (PPAR)-gamma-ligands, there is evidence for some off-target effects mediated by a non-PPARgamma mechanism. Previously we have shown that rosiglitazone has antiinflammatory actions not explicable by activation of PPARgamma,but possibly by the glucocorticoid receptor (GR). Rosiglitazone induces nuclear translocation both of GR-green fluorescent protein, and endogenous GR in HeLa and U20S cells but with slower kinetics than dexamethasone. Rosiglitazone also induces GR phosphorylation (Ser211), a GR ligand-binding-specific effect. Rosiglitazone drives luciferase expression from a simple glucocorticoid-response element containing reporter gene in a GR-dependent manner (EC50 4 microm), with a similar amplitude response to the partial GR agonist RU486. Rosiglitazone also inhibits dexamethasone-driven reporter gene activity (IC50 2.9 microm) in a similar fashion to RU486, suggesting partial agonist activity. Importantly we demonstrate a similar effect in PPARgamma-null cells, suggesting both GR dependence and PPARgamma independence. Rosiglitazone also activates a GAL4-GR chimera, driving a upstream activating sequence promoter, demonstrating DNA template sequence independence and furthermore enhanced steroid receptor coactivator-1-GR interaction, measured by a mammalian two-hybrid assay. Both ciglitazone and pioglitazone, structurally related to rosiglitazone, show similar effects on the GR. The antiproliferative effect of rosiglitazone is increased in U20S cells that overexpress GR, suggesting a biologically important GR-dependent component of rosiglitazone action. Rosiglitazone is a partial GR agonist, affecting GR activation and trafficking to influence engagement of target genes and affect cell function. This novel mode of action may explain some off-target effects observed in vivo. Additionally, antagonism of glucocorticoid action may contribute to the antidiabetic actions of rosiglitazone.
Assuntos
PPAR gama/fisiologia , Receptores de Glucocorticoides/agonistas , Tiazolidinedionas/farmacologia , Divisão Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Dexametasona/antagonistas & inibidores , Dexametasona/farmacologia , Ativação Enzimática , Genes Reporter , Células HeLa , Antagonistas de Hormônios/farmacologia , Humanos , Luciferases/genética , Luciferases/metabolismo , Neoplasias Pulmonares , Mifepristona/farmacologia , Receptores de Glucocorticoides/metabolismo , Rosiglitazona , TransfecçãoRESUMO
In this study we investigated, for the first time in vivo, the effect of cloricromene, a cumarine derivative, on NF-kappaB activation in endotoxin-treated rats. Endotoxemia was induced in male rats by the intravenous injection of Salmonella typhosa lipopolysaccharide (LPS; 2 mg/kg/i.v.). In vivo treatment with cloricromene (2 mg/kg/i.v.) 30 min before lipopolysaccharide administration reversed the LPS-induced loss in tone of the aortic rings, improved their reactivity to phenylephrine, decreased both nitric oxide (NO) and TNF-alpha serum levels by inhibiting LPS-induced inducible NO synthase and TNF-alpha mRNA expression, and interestingly inhibited LPS-induced NF-kappaB activation. Our data suggest that cloricromene protects rats from LPS by blocking LPS-induced NF-kappaB activation, leading to inhibition of NO and TNF-alpha overproduction and thereby reversing the LPS-induced vascular hyporeactivity.
Assuntos
Cromonar/análogos & derivados , Cromonar/uso terapêutico , Endotoxemia/tratamento farmacológico , NF-kappa B/antagonistas & inibidores , Salmonella typhi , Animais , Aorta Torácica/efeitos dos fármacos , Aorta Torácica/metabolismo , Aorta Torácica/fisiologia , Ensaio de Desvio de Mobilidade Eletroforética , Endotoxemia/metabolismo , Endotoxemia/fisiopatologia , Técnicas In Vitro , Masculino , Contração Muscular/efeitos dos fármacos , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/fisiologia , NF-kappa B/genética , NF-kappa B/metabolismo , Nitratos/sangue , Óxido Nítrico Sintase/antagonistas & inibidores , Óxido Nítrico Sintase/genética , Óxido Nítrico Sintase Tipo II , Nitritos/sangue , Fenilefrina , RNA Mensageiro/antagonistas & inibidores , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/genéticaRESUMO
Two ethanolic propolis extracts (EPE) with and without the caffeic acid phenethyl ester (CAPE), CAPE and galangin (major components of propolis) were investigated for anti-inflammatory activity in rats using carrageenin foot oedema, carrageenin pleurisy and adjuvant arthritis. In our experiments, EPE with CAPE and CAPE alone significantly inhibited carrageenin oedema, carrageenin pleurisy and adjuvant arthritis. In contrast EPE without CAPE and galangin did not exhibit anti-inflammatory effects in acute and chronic inflammation. These results suggest that the anti-inflammatory activity of propolis is due to CAPE.
Assuntos
Anti-Inflamatórios/farmacologia , Artrite/prevenção & controle , Edema/prevenção & controle , Álcool Feniletílico/análogos & derivados , Fitoterapia , Pleurisia/prevenção & controle , Própole/farmacologia , Doença Aguda , Animais , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/química , Anti-Inflamatórios/uso terapêutico , Artrite/induzido quimicamente , Ácidos Cafeicos/administração & dosagem , Ácidos Cafeicos/química , Ácidos Cafeicos/farmacologia , Ácidos Cafeicos/uso terapêutico , Carragenina , Divisão Celular/efeitos dos fármacos , Doença Crônica , Edema/induzido quimicamente , Flavonoides/administração & dosagem , Flavonoides/química , Flavonoides/farmacologia , Flavonoides/uso terapêutico , Masculino , Álcool Feniletílico/administração & dosagem , Álcool Feniletílico/química , Álcool Feniletílico/farmacologia , Álcool Feniletílico/uso terapêutico , Extratos Vegetais/administração & dosagem , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Pleurisia/induzido quimicamente , Própole/administração & dosagem , Própole/química , Própole/uso terapêutico , Ratos , Ratos Endogâmicos Lew , Ratos Wistar , Linfócitos T/efeitos dos fármacos , Fatores de TempoRESUMO
OBJECTIVE: In 1996 we found by serendipity that 2 patients with rheumatoid arthritis (RA) who were taking clarithromycin (CM) to eradicate Helicobacter pylori experienced a regression of their RA symptoms. Following this observation, we tested the hypothesis that this reduction in symptoms could have been caused by CM administration. METHODS: We performed a 6-month, open, uncontrolled pilot study on 18 patients (14 females and 4 males, mean age 62 yrs.) with RA who had previously received DMARDs (mean 2.6) and discontinued the treatment at least one month earlier because lack of efficacy or severe side effects. Patients were treated with CM at the dose of 500 mg twice per day for the first 10 days, followed by a daily maintenance dose of 250 mg twice per day. RESULTS: 4/18 patients did not complete the treatment, 2/18 were not responsive to the treatment and 2/18 discontinued the treatment. Following ACR criteria the improvement was: 10 patients ACR 20; 6 patients ACR 50; and 2 patients ACR 70. The remaining 4 patients did not reach ACR 20 since either the number of tender or swollen joints was not to the level required. Reductions in PGE2 and soluble phospholipase A2 plasma levels were closely related to CM plasma levels. CONCLUSIONS: Ourfindings suggest that CM treatment can be beneficial in those patients who are not responsive to or cannot tolerate DMARDs. No definitive conclusions can be drawn based on the present study, due to the small sample size involved.
Assuntos
Antibacterianos/administração & dosagem , Artrite Reumatoide/tratamento farmacológico , Claritromicina/administração & dosagem , Adulto , Antirreumáticos/efeitos adversos , Dinoprostona/sangue , Feminino , Humanos , Masculino , Pacientes Desistentes do Tratamento , Fosfolipases A/sangue , Fosfolipases A2 , Projetos Piloto , Resultado do TratamentoRESUMO
In this study, using rat carrageenin-induced pleurisy, we found that treatment of rats with either indomethacin or NS-398 suppressed the pleurisy at 2 h but significantly exacerbated this reaction at 48 h. Exacerbated inflammation was associated with reduced prostaglandin D(2) levels, decreased heat shock factor 1 (HSF1) activation, reduced hsp72 expression and increased activation of nuclear factor kappaB (NF-kappaB). Replacement of cyclopentenone prostaglandins by treating rats with either prostaglandin J(2) or prostaglandin D(2) reversed the exacerbating effects of cyclooxygenase inhibitors leading to the resolution of the reaction. In conclusion, we demonstrate that cyclopentenone prostaglandins may act as anti-inflammatory mediators by inducing in inflammatory cells HSF1-dependent hsp72 expression and NF-kappaB inhibition, two crucial events for the remission of inflammation.
Assuntos
Proteínas de Choque Térmico/metabolismo , NF-kappa B/metabolismo , Pleura/metabolismo , Pleurisia/metabolismo , Prostaglandina D2/análogos & derivados , Prostaglandina D2/farmacologia , Prostaglandinas/metabolismo , Transporte Ativo do Núcleo Celular/efeitos dos fármacos , Animais , Carragenina , Inibidores de Ciclo-Oxigenase/farmacologia , Proteínas de Ligação a DNA/metabolismo , Modelos Animais de Doenças , Combinação de Medicamentos , Exsudatos e Transudatos/química , Exsudatos e Transudatos/citologia , Proteínas de Choque Térmico HSP72 , Fatores de Transcrição de Choque Térmico , Humanos , Indometacina/farmacologia , Masculino , Subunidade p50 de NF-kappa B , Nitrobenzenos/farmacologia , Pleura/efeitos dos fármacos , Pleurisia/induzido quimicamente , Prostaglandina D2/metabolismo , Prostaglandinas/química , Ratos , Ratos Wistar , Sulfonamidas/farmacologia , Fator de Transcrição RelA , Fatores de TranscriçãoRESUMO
In the present study we investigated in the reverse passive Arthus reaction elicited in the rat skin the anti-inflammatory effect of double-stranded oligodeoxynucleotides (ODN) with consensus nuclear factor-kappaB (NF-kappaB) sequence as transcription factor decoys (TFD) to inhibit NF-kappaB binding to native DNA sites. Local administration of wild-type-, but not mutant-decoy ODN, dose-dependently reduced both plasma leakage and neutrophil infiltration in rat skin. Molecular analysis performed on soft tissue obtained from rat skin demonstrated: (1) an inhibition of NF-kappaB/DNA binding activity; (2) a decreased nuclear level of p50 and p65 NF-kappaB subunits; (3) an inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) protein expression, two inflammatory enzymes transcriptionally controlled by NF-kappaB. Furthermore, SN-50, a cell-permeable peptide capable of inhibiting the nuclear translocation of NF-kappaB complexes, as well as ammonium pyrrolidine dithiocarbamate, an inhibitor of NF-kappaB activation, exhibited a similar profile of activity of decoy ODN. Our results indicate that decoy ODN, acting as an in vivo competitor for the transcription factor's ability to bind to cognate recognition sequence, may represent a novel strategy to modulate immune reactions.
Assuntos
Antioxidantes/farmacologia , Reação de Arthus/metabolismo , NF-kappa B/metabolismo , Pele/efeitos dos fármacos , Tiocarbamatos/farmacologia , Fatores de Transcrição/farmacologia , Análise de Variância , Animais , Ciclo-Oxigenase 2 , DNA/metabolismo , Interações Medicamentosas , Isoenzimas/antagonistas & inibidores , Masculino , Prostaglandina-Endoperóxido Sintases , Pirrolidinas/farmacologia , Ratos , Ratos Wistar , Pele/metabolismoRESUMO
In this study we have investigated the relationship between neointima formation and NF-kappaB activation in a model of endothelial denudation of rat carotid artery (balloon angioplasty) using the antioxidant pyrrolidine dithiocarbamate as inhibitor of NF-kappaB activation. Furthermore, we have correlated NF-kappaB activation to the expression of inducible isoforms of both nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) in injured carotids. In control group a significant proliferation of neointima was observed 14 days after balloon angioplasty, which was correlated to an increase of NF-kappaB/DNA binding activity as well as p50/p65 nuclear levels compared to those observed in the carotids from naive or sham-operated rats. Furthermore, NF-kappaB activation was correlated to increased iNOS and COX-2, but not beta-actin, protein expression. Treatment of rats for 14 days with the antioxidant agent pyrrolidine dithiocarbamate (50, 100, 200 mg/kg per os and day) caused a significant inhibition of all the parameters assayed, except beta-actin protein expression. These results indicate that prevention of NF-kappaB activation may lead to the inhibition of neointima formation and suggest that antioxidant agents may have therapeutic relevance for the prevention of human restenosis.
Assuntos
Vasos Sanguíneos/lesões , NF-kappa B/fisiologia , Angioplastia com Balão , Animais , Antioxidantes/farmacologia , Vasos Sanguíneos/efeitos dos fármacos , Western Blotting , Artérias Carótidas/efeitos dos fármacos , Artérias Carótidas/fisiologia , Ciclo-Oxigenase 2 , Densitometria , Ensaio de Desvio de Mobilidade Eletroforética , Endotélio Vascular/efeitos dos fármacos , Isoenzimas/biossíntese , Masculino , NF-kappa B/antagonistas & inibidores , Óxido Nítrico Sintase/biossíntese , Óxido Nítrico Sintase Tipo II , Testes de Precipitina , Antígeno Nuclear de Célula em Proliferação/metabolismo , Prostaglandina-Endoperóxido Sintases/biossíntese , Pirrolidinas/farmacologia , Ratos , Ratos Wistar , Tiocarbamatos/farmacologiaRESUMO
A detailed analysis of the toxic composition in the hepatopancreas of mussels from northern Adriatic sea has been performed. Along with some polyether toxins of DSP (diarrhetic shellfish poisoning) type, such as yessotoxin and its analogues, which are responsible for a variety of human seafood poisonings throughout the world, we have now isolated a new type of toxin, the chlorosulfolipid 1, which is completely different in structure from the polyether DSP-toxins isolated so far. The structural determination of the new toxin, including its absolute stereochemistry, has been performed by extensive NMR analysis and molecular mechanics and dynamics calculations.
Assuntos
Bivalves/química , Sistema Digestório/química , Lipídeos/química , Lipídeos/toxicidade , Toxinas Marinhas/química , Animais , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Doenças Transmitidas por Alimentos/etiologia , Humanos , Lipídeos/isolamento & purificação , Toxinas Marinhas/isolamento & purificação , Água do Mar , Frutos do MarRESUMO
We investigated the occurrence and the role of HSF1 activation and inducible hsp72 expression in the carrageenin pleurisy in the rat. Molecular analysis performed on pleural cells collected from rat pleural cavity after carrageenin challenge revealed increased HSF1 activation and hsp72 expression. Moreover, local injection of a double-stranded oligodeoxynucleotide (ODN) containing the heat shock element sequence, acting as transcription factor decoy, exacerbated the inflammatory reaction. The exacerbation, induced by wild-type, but not by mutant ODN decoy, was associated to both inhibition of HSF1/DNA binding activity and reduction of hsp72 expression. In conclusion, this study shows that HSF1 activation and hsp72 expression both actually occur in acute inflammation and that the remission of the inflammatory reaction is tightly associated to the HSF1-dependent hsp72 expression, suggesting a a relevant role for the HSF1/hsp72 pathway as an endogenous anti-inflammatory system.
Assuntos
Proteínas de Ligação a DNA/metabolismo , Proteínas de Choque Térmico/metabolismo , Pleurisia/metabolismo , Animais , Anti-Inflamatórios/metabolismo , Carragenina , DNA Antissenso/farmacologia , Proteínas de Ligação a DNA/antagonistas & inibidores , Proteínas de Ligação a DNA/genética , Modelos Animais de Doenças , Exsudatos e Transudatos/metabolismo , Expressão Gênica/efeitos dos fármacos , Proteínas de Choque Térmico HSP72 , Fatores de Transcrição de Choque Térmico , Masculino , Pleurisia/induzido quimicamente , Ratos , Ratos Wistar , Fatores de Tempo , Fatores de TranscriçãoRESUMO
SV-IV is a basic, thermostable, secretory protein of low Mr (9758) that is synthesized by rat seminal vesicle (SV) epithelium under strict androgen transcriptional control. This protein is of obvious pharmacological interest because it has potent nonspecies-specific immunomodulatory, anti-inflammatory, and pro-coagulant activities. In evaluating the clinical relevance and the possible use in medicine of SV-IV, we became interested in the study of its structure-function relationships and aimed to identify in its polypeptide chain specific peptide fragments possessing the marked anti-inflammatory properties of the protein not associated with other biological activities (pro-coagulation and immunomodulation) typical of this molecule. By using two different experimental approaches (the fragmentation of the protein into peptide derivatives by chemical methods and the organic synthesis on solid phase of selected peptide fragments), data were obtained showing that in this protein: (a) the immunomodulatory activity is related to the structural integrity of the whole molecule; (b) the anti-inflammatory activity is located in the N-terminal region of the molecule, the 8-16 peptide fragment being the most active; (c) the identified anti-inflammatory peptide derivatives do not seem to possess pro-coagulant activity, even though this particular function has been located in the 1-70 segment of the molecule.
Assuntos
Anti-Inflamatórios/síntese química , Fragmentos de Peptídeos/síntese química , Proteínas/química , Proteínas Secretadas pela Vesícula Seminal , Sequência de Aminoácidos , Animais , Anti-Inflamatórios/química , Coagulantes/síntese química , Coagulantes/química , Brometo de Cianogênio/química , Imunossupressores/síntese química , Imunossupressores/química , Masculino , Dados de Sequência Molecular , Fragmentos de Peptídeos/química , Ratos , Ratos WistarRESUMO
A (1 --> 3)-beta-D-glucan with approximately 30% of the residues having a beta-D-Glc-(1 --> 6) branch is the main water-soluble component of the cell wall polysaccharide of Cryphonectria parasitica (Murr.) Barr strain 263. A (1 --> 3)-glucan with both alpha and beta anomeric linkages was found in the water-insoluble polysaccharide fraction. Both fractions possess immunological activity, being able to induce the production of either tumour necrosis factor alpha (TNF-alpha) or nitrite (NO2-).
Assuntos
Adjuvantes Imunológicos/isolamento & purificação , Ascomicetos/química , Parede Celular/química , Glucanos/isolamento & purificação , Adjuvantes Imunológicos/química , Animais , Configuração de Carboidratos , Sequência de Carboidratos , Indução Enzimática , Glucanos/química , Glucanos/farmacologia , Lipopolissacarídeos/farmacologia , Macrófagos/metabolismo , Espectroscopia de Ressonância Magnética , Camundongos , Dados de Sequência Molecular , Proteínas de Neoplasias/metabolismo , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo II , Nitritos/metabolismo , Polissacarídeos/análise , Solubilidade , Relação Estrutura-Atividade , Células Tumorais Cultivadas , Fator de Necrose Tumoral alfa/metabolismo , ÁguaRESUMO
The transcription factor nuclear factor-kappaB (NF-kappaB) plays a key role in the expression of several genes involved in the inflammatory process. In the present study we investigated in an acute model of inflammation, the carrageenin-induced hind paw edema, the anti-inflammatory effect of double stranded oligodeoxynucleotides (ODN) with consensus nuclear factor-kappaB (NF-kappaB) sequence as transcription factor decoys (TFD) to inhibit NF-kappaB binding to native DNA sites. Local administration of wild-type, but not mutant-ODN decoy, dose-dependently inhibited edema formation induced by carrageenin in rat paw. Molecular analysis performed on soft tissue obtained from inflamed paw demonstrated: (1) an inhibition of NF-kappaB DNA binding activity; (2) a decreased nuclear level of p50 and p65 NF-kappaB subunits; (3) an inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) protein expression, two inflammatory enzymes transcriptionally controlled by NF-kappaB. Furthermore, SN-50, a cell-permeable peptide capable of inhibiting the nuclear translocation of NF-kappaB complexes, exhibited a similar profile of activity of ODN decoy. Our results indicate for the first time that ODN decoy, acting as an in vivo competitor for the transcription factor's ability to bind to cognate recognition sequence, may represent a novel strategy to modulate acute inflammation.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Inflamação/prevenção & controle , NF-kappa B/genética , Oligonucleotídeos/uso terapêutico , Doença Aguda , Animais , Ligação Competitiva , Carragenina , Ciclo-Oxigenase 2 , Inflamação/induzido quimicamente , Inflamação/metabolismo , Isoenzimas/metabolismo , Masculino , NF-kappa B/metabolismo , Óxido Nítrico Sintase/metabolismo , Prostaglandina-Endoperóxido Sintases/metabolismo , Ratos , Ratos WistarRESUMO
OBJECTIVE AND DESIGN: The role of nitric oxide (NO) on leucocyte migration has been investigated in rat carrageenin-induced pleurisy. MATERIAL: Male Wistar rats. TREATMENT: L-arginine, NOC-18 and aminoguanidine were administered subcutaneously 1 h prior to carrageenin injection. METHODS: Leucocyte accumulation into the pleural cavity was measured 4 h after carrageenin challenge. Statistical significance was calculated by Bonferroni test. RESULTS: L-arginine (10 mg/kg) or the NO donor NOC-18 (10 mg/kg), significantly inhibited leucocyte infiltration by 31% and 20% respectively (P<0.01). On the contrary, when these compounds were given at high doses (L-arginine 300 mg/kg; NOC-18 30 mg/kg), leucocyte accumulation was increased by 22% and 33% respectively (P<0.01). Aminoguanidine, a relatively selective inhibitor of the inducible NO synthase, depending on the dose, showed a biphasic effect on cell migration. Thus, at low doses (30 and 100 mg/kg), aminoguanidine increased (by 40% and 74% respectively, P< 0.01) leucocyte infiltration which was inhibited by 41% (P < 0.01) when the drug was given at high dose (300 mg/kg). CONCLUSIONS: These results suggest that in rat carrageenin-induced pleurisy NO primarily inhibits leucocyte migration.
Assuntos
Carragenina , Movimento Celular/efeitos dos fármacos , Leucócitos/fisiologia , Óxido Nítrico/farmacologia , Pleurisia/patologia , Animais , Arginina/administração & dosagem , Arginina/farmacologia , Pressão Sanguínea , Inibidores Enzimáticos/farmacologia , Guanidinas/administração & dosagem , Guanidinas/farmacologia , Masculino , Doadores de Óxido Nítrico/administração & dosagem , Doadores de Óxido Nítrico/farmacologia , Óxido Nítrico Sintase/antagonistas & inibidores , Óxido Nítrico Sintase Tipo II , Compostos Nitrosos/administração & dosagem , Compostos Nitrosos/farmacologia , Pleura/patologia , Derrame Pleural/patologia , Derrame Pleural/fisiopatologia , Pleurisia/induzido quimicamente , Ratos , Ratos WistarRESUMO
An extensive phytochemical analysis of the saponin content has been undertaken on leek, Allium porrum L., sown and collected at different seasons. As a result of this investigation, eight saponins (1-8) have been isolated, four of them (5-8) being novel compounds. Compounds 5 and 6, possessing the same tetrasaccharide moiety of compounds 1 and 3, display very unusual spirostane aglycones, 12-ketoporrigenin and 2,12-diketoporrigenin (named porrigenin C), respectively, recently isolated for the first time as free sapogenin in the same plant. Compounds 7 and 8 are rare cholestane bidesmosides possessing a di- and trisaccharide residues linked to a polyhydroxycholesterol aglycone, respectively. The structures of the isolated compounds have been determined by nondegradative spectroscopic analysis, mainly based on NMR. All the eight saponins isolated from leek were tested for their cytotoxic activity against two different cell lines in vitro, and compounds 1, 2, and 6 resulted particularly active.
Assuntos
Allium/química , Antineoplásicos Fitogênicos/isolamento & purificação , Saponinas/isolamento & purificação , Animais , Antineoplásicos Fitogênicos/química , Antineoplásicos Fitogênicos/farmacologia , Sequência de Carboidratos , Ensaios de Seleção de Medicamentos Antitumorais , Camundongos , Dados de Sequência Molecular , Saponinas/química , Saponinas/farmacologia , Células Tumorais CultivadasRESUMO
1. Anti-inflammatory non steroidal drugs releasing NO (NO-NSAIDs) are a new class of anti-inflammatory drugs to which has been added an NO-releasing moiety. These compounds have been shown to retain the anti-inflammatory, analgesic and antipyretic activity of the parent compound but to be devoid of gastrointestinal (GI) toxicity. 2. Freund's adjuvant (FA) arthritis was induced in rats by a single intraplantar injection into the right hindpaw of 100 microl of mycobacterium butirricum (6 mg ml(-1)). The effect of equimolar doses of naproxen (1, 3 and 10 mg kg(-1)) and NO-naproxen (1.5, 4.5 and 16 mg kg(-1)) was evaluated using two dosage regimen protocols: (i) preventive, starting oral administration of the drugs at the time of induction of arthritis and for the following 21 days (day 1 - 21); (ii) therapeutic, starting oral administration of the drugs 7 days after adjuvant injection and for the following 14 days (day 7 - 21). 3. Hindpaw swelling (days 3, 7, 11, 14, 17, 21) and nociception (days 15 and 21) were measured. On day 22 rats were sacrificed, draining lymph nodes were removed and T cells isolated. In vitro proliferation of T cells following stimulation with concanavalin A (0.5 - 5 microg ml(-1)) was measured using a tritiated thymidine incorporation assay. IL-2 receptor expression on T cells was measured by FACS analysis. 4. Naproxen and NO-naproxen showed similar activity in reducing oedema formation in the non-injected (controlateral) hindpaw. Both drugs showed anti-nociceptive effect. NO-naproxen was anti-nociceptive at a dose of 4.5 mg kg(-1) while naproxen showed the same extent of inhibition only at a dose of 10 mg kg(-1). 5. T cells were isolated and characterized by FACS analysis. Stimulation of isolated T cells with concanavallin A in vitro caused a significant increase in thymidine uptake. NO-naproxen at a dose of 4.5 mg kg(-1) inhibited T cell proliferation to the same extent as 10 mg kg(-1) of naproxen. 6. Inhibition of T cell proliferation was well correlated with reduced IL-2 receptor expression on T cells. In addition, NO-naproxen reduced both IL-1beta and TNFalpha plasma levels whilst naproxen reduced IL-1beta levels only. 7. In conclusion, both naproxen and NO-naproxen reduce inflammation and nociception associated with arthritis. In addition NO-naproxen interferes to a larger extent with cellular mechanism involved in T cell activation in rat adjuvant arthritis indicating that introduction of the NO moiety in the naproxen structure increases the effect at the level of the immune system.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Artrite Experimental/prevenção & controle , Inflamação/prevenção & controle , Naproxeno/análogos & derivados , Óxido Nítrico/farmacologia , Nociceptores/efeitos dos fármacos , Linfócitos T/efeitos dos fármacos , Animais , Artrite Experimental/imunologia , Artrite Experimental/fisiopatologia , Relação Dose-Resposta a Droga , Edema/prevenção & controle , Citometria de Fluxo , Membro Posterior , Interleucina-1/sangue , Masculino , Naproxeno/farmacologia , Dor/prevenção & controle , Medição da Dor , Ratos , Ratos Endogâmicos Lew , Receptores de Interleucina-2/efeitos dos fármacos , Receptores de Interleucina-2/metabolismo , Linfócitos T/imunologia , Linfócitos T/metabolismo , Timidina/metabolismo , Fatores de Tempo , Fator de Necrose Tumoral alfa/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Rats injected in the hind paw with a mixture of Mycobacterium butirricum emulsified in mineral oil (FA) developed a severe polyarthritis that shared some immunological features with human rheumatoid arthritis. After this local administration, rats developed a secondary lesion (edema) in the contralateral paw, which is a hallmark of immune system activation. In vivo intravenous treatment with a monoclonal anti-very late antigen (VLA)-1 antibody (HA31/8) significantly reduced the edema formation in the contralateral paw. T cells isolated from contralateral paw draining lymph nodes of FA rats treated with HA31/8 showed a reduced cell proliferation in vitro, after stimulation with concanavalin A. Furthermore FACS analysis showed that the reduction in proliferation was concomitant to a reduction in the number of T cells positive to surface IL-2 receptor expression. Our data indicate that after in vivo treatment with a monoclonal anti-very late antigen-1 antibody, there is a beneficial effect on the development of the secondary lesion, which correlates to the reduced ability of T cells to proliferate in vitro as well as to a reduced surface expression of IL-2 receptor. The association of this antibody to other drugs interfering at other levels in rheumatoid arthritis may open a new therapeutic window.